Figure 7.
The efficacy of combination therapy with bevacizumab and clone 1760. DISS cells were injected s.c. in the dorsal flank of BALB/c nude mice at 1 × 106 cells/mouse. Mice were treated with 5 mg/kg of mouse IgG, 25 mg/kg of hVASH2 mAb, 5 mg/kg of bevacizumab or 25 mg/kg of hVASH2 mAb plus 5 mg/kg of bevacizumab i.p. twice per week, and tumor growth was monitored. Experiments were repeated at least twice to confirm the reproducibility. Representative data are presented as the mean and SD (n = 8). *P < 0.05 (vs IgG). NS, not significant.